baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Amarin Corp PLC/ US0231112063 /

2024-05-13 10:00:00 PM	Chg. +0.0675	Volume	Bid10:00:37 AM	Ask10:00:37 AM	High	Low
0.9200USD	+7.92%	1.04 mill. Turnover: 925,191.1889	0.8540Bid Size: 700	0.9800Ask Size: 1,500	0.9499	0.8600

GlobeNewswire 05-06 Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire 05-01 Amarin Reports First Quarter 2024 Business Update and Financial Results

GlobeNewswire 04-24 Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate P...

GlobeNewswire 04-22 ArriVent Appoints Kristine Peterson to its Board of Directors

GlobeNewswire 04-22 Amarin Announces Results of Annual General Meeting of Shareholders

GlobeNewswire 04-15 Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

GlobeNewswire 04-08 Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

GlobeNewswire 04-06 New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular...

GlobeNewswire 04-03 Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

GlobeNewswire 03-25 Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American ...

GlobeNewswire 03-22 Theratechnologies Appoints Jordan Zwick to its Board of Directors

GlobeNewswire 02-29 Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 02-15 Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February...

GlobeNewswire 01-22 Amarin Chairman & CEO Issue Letter to Shareholders

GlobeNewswire 01-10 Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For ...

GlobeNewswire 2023-12-11 Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-04 Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Oth...

GlobeNewswire 2023-11-12 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Red...

GlobeNewswire 2023-11-01 Amarin Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-31 Lexicon Strengthens Management Team With Two New Executives

GlobeNewswire 2023-10-31 Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

GlobeNewswire 2023-10-26 Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Land...

GlobeNewswire 2023-10-19 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

GlobeNewswire 2023-09-12 Amarin to Present at the 2023 Cantor Global Healthcare Conference

GlobeNewswire 2022-03-28 Amarin Receives Reimbursement for VAZKEPA® in Sweden

Amarin Corp PLC/ US0231112063 /

If you wish to receive reply to your feedback, please provide your email address.